Skip to Content

Zarnestra Approval Status

  • FDA approved: No
  • Brand name: Zarnestra
  • Generic name: tipifarnib
  • Dosage form: Oral
  • Previous name: R115777
  • Company: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  • Treatment for: Acute Myeloid Leukemia

Zarnestra (tipifarnib) is a farnesyltransferase inhibitor intended for use in the treatment of acute myeloid leukemia (AML) in elderly patients who are not candidates for standard chemotherapy.

In June 2005, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced the receipt of a not approvable letter from the U.S. Food and Drug Administration (FDA) for the tipifarnib new drug application (NDA), advising the NDA could not be approved based on the submitted data.

Development Status and FDA Approval Process for Zarnestra

Jun 30, 2005Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Receives Not Approvable Letter From FDA for Tipifarnib Based on Phase II Data
Jan 24, 2005Johnson & Johnson Completes Submission of Tipifarnib NDA to FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.